Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus XOFIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus XOFIGO.
MACROTEC vs XOFIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Radium-223 dichloride is a calcium-mimetic alpha particle-emitting radiopharmaceutical that forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The alpha particles induce double-strand DNA breaks in adjacent cells, resulting in cytotoxic effects.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
55 kBq (1.49 microcurie) per kg body weight, intravenous injection every 4 weeks.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
The terminal elimination half-life of radium-223 dichloride is approximately 11 days (range 7–14 days), reflecting the slow turnover of radium in bone.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Radium-223 dichloride is primarily excreted via the feces. Approximately 75% of the administered dose is eliminated in feces within 7 days, with a smaller fraction (about 5%) excreted in urine.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical